- Home
- TLPH vs ATHA Comparison
TLPH vs ATHA Comparison
Compare TLPH & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- ATHA
- Stock Information
- Founded
- TLPH 2005
- ATHA 2011
- Country
- TLPH United States
- ATHA United States
- Employees
- TLPH N/A
- ATHA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- TLPH Health Care
- ATHA Health Care
- Exchange
- TLPH Nasdaq
- ATHA Nasdaq
- Market Cap
- TLPH 10.6M
- ATHA 10.6M
- IPO Year
- TLPH 2011
- ATHA 2020
- Fundamental
- Price
- TLPH $0.44
- ATHA $0.30
- Analyst Decision
- TLPH Strong Buy
- ATHA Buy
- Analyst Count
- TLPH 1
- ATHA 4
- Target Price
- TLPH $6.00
- ATHA $11.25
- AVG Volume (30 Days)
- TLPH 31.7K
- ATHA 1.3M
- Earning Date
- TLPH 08-13-2025
- ATHA 07-31-2025
- Dividend Yield
- TLPH N/A
- ATHA N/A
- EPS Growth
- TLPH N/A
- ATHA N/A
- EPS
- TLPH N/A
- ATHA N/A
- Revenue
- TLPH $27,000.00
- ATHA N/A
- Revenue This Year
- TLPH N/A
- ATHA N/A
- Revenue Next Year
- TLPH $14,533.26
- ATHA N/A
- P/E Ratio
- TLPH N/A
- ATHA N/A
- Revenue Growth
- TLPH N/A
- ATHA N/A
- 52 Week Low
- TLPH $0.44
- ATHA $0.22
- 52 Week High
- TLPH $1.19
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- TLPH 31.91
- ATHA 47.43
- Support Level
- TLPH $0.45
- ATHA $0.29
- Resistance Level
- TLPH $0.52
- ATHA $0.35
- Average True Range (ATR)
- TLPH 0.03
- ATHA 0.03
- MACD
- TLPH -0.00
- ATHA -0.00
- Stochastic Oscillator
- TLPH 0.00
- ATHA 23.71
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.